Professor Malcolm Young

CEO

Professor Malcolm Young is a scientist by background. He has previously been Director of the Complex Systems Group; Director of the Institute for Neuroscience; Provost of the Faculty of Science, Agriculture and Engineering; and Pro-Vice Chancellor for Strategic Development at Newcastle University, after having been a Royal Society Research Fellow at the RIKEN Institute in Japan, and at Oxford University.

His research expertise lies in complex systems analysis and informatics, and his research outputs include 6 publications in Nature and Science and 12 in Proceedings and Philosophical Transactions of the Royal Society. The main goals of his research were to understand how biological function arises from structural aspects of complex biological systems.

He is one of eighteen scientists worldwide nominated by the Sunday Times as the "Brains behind the 21st Century". Professor Young founded e-Therapeutics, and has led its development since.

Contact Malcolm

Steve Self

Development Director

Steve Self began his career in Chemistry in 1975 with The Wellcome Foundation. He held positions in both R&D and Operations before being appointed as a full time Project Manager in Wellcome Research in 1987. He became Head of Project management in 1991, and was appointed Group Vice-President for Project Management in 1993.

Steve Joined Boots Healthcare International in 1995 as Head of Respiratory and Analgesic product development, before joining Merck Generics in 1997 as European Technical Director. He was appointed as MGG’s Group R&D Director in 1999, and stayed with Merck until the sale of the company to Mylan in 2007. Since then he has worked for a private equity bank on major US pharmaceutical acquisitions, before joining e-Therapeutics to drive the Company’s clinical development activities.

Dr Daniel Elger

Chief Financial Officer

Daniel Elger has 17 years' experience in healthcare businesses. He began his career in medical publishing. He then spent five years at pharmaceutical marketing consultancies Blackwell Healthcare and Avenue, becoming a Programme Director in 1999 and leading accounts for GSK, Janssen, Roche, Pfizer and Merck.

In 2002 Daniel joined cancer drug developer Antisoma as Head of Corporate Communications, becoming Communications Director in 2005 and VP, Marketing & Communications in 2008. He served on the Senior Management Team and played significant roles in corporate strategy, fundraisings and the acquisition of two US biotech companies.

Daniel has a BA in Physiological Sciences (Medicine) and a PhD in cancer cell biology, both from Oxford University.

Contact Daniel

Professor Oliver Francis Wintour James

Non-executive Chairman

Oliver has been a non-executive director of BUPA since 1999 and was a non-executive director of Goldsborough Health Care plc from when it floated on the main market in 1995, until it was acquired by BUPA in 1997. He has also been a non-executive director of the Newcastle upon Tyne Hospitals NHS Foundation Trust since 2006.

Oliver qualified as a physician in 1975 and practised until 2004 when he became Head of the medical faculty at Newcastle University. He was Senior Vice President of the Royal College of Physicians from 1997 to 1999, and has been a member of many national and governmental medical related boards and committees. Oliver joined the Company as a non-executive director in October 2007.

Contact Oliver

Mr Brad Hoy

Non-executive Director

Brad has over fifteen years of commercial experience in the pharmaceutical and biotechnology industries through financial and general management roles in the UK and USA.

Brad is Director and co-founder of Seven Hills Venture Partners Ltd, a life sciences advisory firm based in Edinburgh. Previously Brad was Chief Financial Officer of Plethora Solutions Holdings plc, an AIM-listed speciality pharmaceutical company, Chief Executive Officer of Xcellsyz Ltd, a UK venture capital-backed life science company, and Senior Director of Geron Corporation’s stem cell-focussed UK subsidiary.
Prior to co-founding Seven Hills, Brad was Chief Financial Officer at Cyclacel Ltd, a UK oncology company, and he held senior financial management positions at ChiRex Inc, a US-based pharmaceutical CMO. Brad is a Chartered Management Accountant.

Dr Rajesh Chopra

Non-executive Director

Raj Chopra is Vice President of Translational and Early Drug Development at Celgene Corporation. He leads a group of around 100 people working to integrate drug discovery and clinical development at Celgene sites in San Diego and San Francisco, CA, Summit, NJ, and Seville, Spain.

Raj has extensive experience of all phases of drug development, in drug portfolio management including acquisition of new assets, and of dealing with regulators and government agencies. Before joining Celgene, he spent five years at AstraZeneca in the US and the UK, culminating in the role of Medical Science Director, Senior Principal Scientist and Disease Area Team Leader for blood cancers. He also has a distinguished track record as a clinician, academic and scientist in the UK, including seven years as Clinical Director of the Department of Haematological Oncology at the Christie Hospital, Manchester.

Raj holds a BSc and an MBBS from University College and Middlesex School of Medicine, University of London and a PhD from the University of London. He is a Fellow of both the Royal College of Physicians and the Royal College of Pathologists in the UK. Raj joined the Board of e-Therapeutics in February 2012.